About US
Contact us
-
Valeant Eyes Medicis ApproachValeant Pharmaceuticals has followed up its recent spate of acquisitions with an approach for US pharmaceutical company Medicis Pharmaceutical. Valeant could be about to follow up its plans to beco2011/8/9
-
US Drug Approvals in 2011 Reach 2010 TotalThe number of new drug approvals in the US in 2011 reached 2010 levels in July, a report compiled by life sciences financial services firm Burrill & Co has confirmed. The US Food and Drug Admi2011/8/8
-
Comprehensive patent search on Omega-3-acid ethyl estersReportlinker.com announces that a new market research report is available in its catalogue: Omega-3-acid ethyl esters - Comprehensive patent search Eliminate unnecessary risk with the industry b2011/8/5
-
Scientists say antibiotic-resistant salmonella strain may spread worldwide"Scientists have identified an emerging 'superbug' strain of salmonella that is highly resistant to the antibiotic Ciprofloxacin, or Cipro, often used for severe salmonella infections, and say they fe2011/8/5
-
SFDA issues The Second National Drug Quality Announcement of 2011The State Food and Drug Administration (SFDA) issued on July 25, 2011 the Second National Drug Quality Announcement of 2011, and released the quality sampling and testing results of 17 national essent2011/8/4
-
Pfizer Looks to Sell Over-the-Counter LipitorPfizer is hoping to sell an over-the-counter version of its cholesterol-lowering drug Lipitor (atorvastatin). The company loses its patent on the world's best-selling drug in November and so hopes to2011/8/4
-
FDA Notifies Pharmaceutical Companies that Studies Conducted by Cetero Research May Require ReevaluationThe FDA is notifying pharmaceutical companies that bioanalytical studies conducted by Cetero Research, Houston, Texas (Cetero) between April 2005 and June 2010 in support of marketing applications may2011/8/3
-
Bayer Sees Sales and Operating Results Rise AgainBayer Group's sales edged closer to the €10bn ($14.4bn) mark, rising 0.8% over last year's figure to €9.25bn ($13.36bn). The company's earnings before interest and tax increased 25.9% to €1.27bn (2011/8/2
-
Mergers Wreck Pharma R&D, Says Ex Pfizer ChiefMergers and acquisitions in the pharmaceutical industry will significantly shrink drug research over the long-term, according to former Pfizer R&D chief John LaMattina. Writing in the online jo2011/8/2
-
FDA approves Lannett's ANDA for Phentermine Resin Extended-Release CapsulesLannett Company, Inc. (NYSE AMEX: LCI) today announced the U.S. Food and Drug Administration (FDA) approved its Abbreviated New Drug Application (ANDA) for Phentermine Resin Extended-Release Capsules,2011/8/1